Shailendra Upadhyay

Dr. Shailendra Upadhyay

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
EKEric V. Krieger
Eric V. Krieger
KZKatja Zeppenfeld
Katja Zeppenfeld
EDElizabeth S. DeWitt
Elizabeth S. DeWitt
VDValeria E. Duarte
Valeria E. Duarte
AEAlexander C. Egbe
Alexander C. Egbe
CCCouncil On Clinical Cardiology
Council On Clinical Cardiology
Arrhythmia and sudden cardiac death remain common in repaired tetralogy of Fallot and affect even those with excellent anatomic repairs. Atrial arrhythmia often has mechanisms different from those in acquired heart disease. Ventricular arrhythmia remains a major source of mortality in repaired tetralogy of Fallot. Noninvasive risk stratification is important to identify patients who may benefit from ablation or primary prevention implantable cardioverter defibrillators. Multiple noninvasive risk factors are associated with ventricular arrhythmia, but no universally accepted risk stratification algorithm exists. The mechanism of ventricular arrhythmia is usually attributable to a consistent and discrete set of slowly conducting anatomic isthmuses related to both the native anatomy and the consequences of the surgical repair, which interact with ventricular remodeling to provide arrhythmic substrate. This substrate can be identified during electroanatomic mapping and prophylactically ablated in appropriate patients. This scientific statement discusses the mechanisms and treatment of arrhythmia in repaired tetralogy of Fallot.

1 April 2021 in JACC
Verified
Journal Article
Closed access
CBCraig S. Broberg
Craig S. Broberg
AKAdrienne H. Kovacs
Adrienne H. Kovacs
SSSoraya Sadeghi
Soraya Sadeghi
MRMarlon S. Rosenbaum
Marlon S. Rosenbaum
MLMatthew J. Lewis
Matthew J. Lewis
JAJamil A. Aboulhosn
Jamil A. Aboulhosn

1 June 2016 in Heart Rhythm
Verified
Journal Article
Closed access
Shailendra UpadhyayShailendra Upadhyay
Shailendra Upadhyay
AVAnne Marie Valente
Anne Marie Valente
JTJohn K Triedman
John K Triedman
EWEdward P. Walsh
Edward P. Walsh

26 August 2017 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
Shailendra UpadhyayShailendra Upadhyay
Shailendra Upadhyay
EWEdward P. Walsh
Edward P. Walsh
FCFrank Cecchin
Frank Cecchin
JTJohn K. Triedman
John K. Triedman
JVJuan Villafane
Juan Villafane
JSJ. Philip Saul
J. Philip Saul

1 January 2011 in International Journal of Critical Illness and Injury Science
Verified
Journal Article
Open access
PDF file
Shailendra UpadhyayShailendra Upadhyay
Shailendra Upadhyay
SMStephen Marshalko
Stephen Marshalko
CMCraig McPherson
Craig McPherson
Proximal right coronary artery occlusion caused transient loss of sensing and capture of the atrial lead of a permanent dual-chamber pacemaker. Forty-five days after percutaneous revascularization, the atrial lead was discovered to be functioning normally. We hypothesize that ischemia of the right atrium caused stunning of the atrial myocardium at the pacer-lead interface, which gradually improved following percutaneous coronary intervention (PCI), leading to return of lead function over time. So far only one similar case has been described in the literature.

26 November 2015 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
OTOlga H. Toro-Salazar
Olga H. Toro-Salazar
EGEileen Gillan
Eileen Gillan
JFJoanna Ferranti
Joanna Ferranti
AOAndrea Orsey
Andrea Orsey
KRKaren Rubin
Karen Rubin
KHKan N. Hor
Kan N. Hor
Subacute cardiotoxicity, consisting of acute myocyte damage and associated left ventricular dysfunction, occurs early during anthracycline therapy. We investigated the impact of myocardial dysfunction, defined herein by a shortening fraction (SF) < 29 % at any time during or after anthracycline therapy, on late onset cardiomyopathy and all-cause mortality, among childhood cancer survivors exposed to anthracyclines. In addition, we sought to identify subpopulations of subjects at highest risk for cardiomyopathy and death from all causes. Five hundred thirty-one childhood cancer survivors exposed to anthracyclines were enrolled and studied on average 10 (1.4–27.3) years following their initial exposure. The medical records were reviewed to identify known risk factors associated with cardiotoxicity, including cumulative anthracycline dose, length of post-therapy interval, administration of other cardiotoxic medications (vinca alkaloids), previous heart disease, radiation dose to the heart, history of bone marrow transplantation, age at treatment, gender, systolic dysfunction, and history of congestive heart failure during anthracycline therapy. Ninety subjects (16.9 %) developed SF < 29 % and 71 patients (13.4 %) died on average 10 years after initial exposure (range 1.4–27.3 years). Total cumulative dose (OR 3.27, 95 % CI 1.94, 5.49, p < 0.001) and bone marrow transplantation (OR 2.57, 95 % CI 1.24, 5.30, p = 0.01) were found to be statistically significant risk factors for development of myocardial dysfunction. There was a 3-fold increase in the odds of having a SF < 29 % at any point during or following cancer therapy if a subject underwent bone marrow transplantation or had a total cumulative dose anthracycline therapy ≥ 240 mg/m2. The all-cause mortality ratio was almost seven-fold higher (95 % CI, 2.40-fold to 17.81-fold higher) if a subject developed systolic dysfunction, defined by a previous SF < 29 % anytime during or after anthracycline therapy. Nine deaths (12.7 %) were attributed to cardiovascular disease. The risk of dying as a result of cardiac disease also was significantly higher in individuals who had a SF < 29 % at any time during or after therapy. This study demonstrates an almost seven-fold increase in all cause mortality in pediatric cancer survivors with a history of anthracycline induced myocardial dysfunction defined as SF < 29 %.